As reported elsewhere [29], preliminary evaluation of pre- and post-Ad-p53 treatment biopsies were evaluated for changes in gene-expression profiles and revealed increased interferon signaling, CD8 + T-cell signaling and the tumor inflammation signature, which are all associated with increased responses to immune checkpoint inhibitors [17, 18, 30]. The gene discussed is CD8A; the disease is neoplasm.